热门资讯> 正文

Kyverna Therapeutics任命Greg Martini为首席财务官

2026-05-18 20:16

Ironwood医药(IRWD) 0

Kyverna Therapeutics (KYTX) said on Monday it appointed Greg Martini as chief financial officer as the company prepares for a potential commercial launch of its autoimmune disease cell therapy candidate miv-cel.
Martini joins Kyverna from Ironwood Pharmaceuticals (IRWD), where he served as senior vice president and CFO.
He succeeds Marc Grasso, who will remain with the company in a consulting role during the transition.
Kyverna is advancing miv-cel, also known as KYV-101, toward a potential first approval in stiff person syndrome.

More on Kyverna Therapeutics

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Kyverna begins rolling BLA submission for miv-cel
Kyverna rises on new mid-stage trial data for myasthenia gravis therapy

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。